Bristol-Myers Squibb Co. (BMY)

51.61
0.69 1.32
NYSE : Health Technology
Prev Close 52.30
Open 52.35
Day Low/High 51.51 / 52.54
52 Wk Low/High 51.56 / 70.05
Volume 17.11M
Avg Volume 8.15M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 88.42B
EPS 0.60
P/E Ratio 85.87
Div & Yield 1.60 (2.90%)

Latest News

Jim's Daily Rundown

Today, Jim discusses Raytheon, tensions in Syria, bank earnings, Kohl's, Nordstrom and more!

Merck Notches Key Win Over Bristol-Myers on Lung Cancer Study Data

Merck Notches Key Win Over Bristol-Myers on Lung Cancer Study Data

The drugmakers on April 16 released data from their respective studies at the Association for Cancer Research's annual meeting in Chicago.

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

Jim Cramer: Possible Jarring Events Will Be Hard for the Market to Ignore

Jim Cramer: Possible Jarring Events Will Be Hard for the Market to Ignore

Let's puzzle over Syria and the possibility of another 'Saturday Night Massacre.'

Syria Crisis Doesn't Affect Bristol-Myers (It Could Help Amazon): Cramer Insider

Syria Crisis Doesn't Affect Bristol-Myers (It Could Help Amazon): Cramer Insider

If President Trump is too busy to post anti-Amazon tweets, that's good news for the online retailer.

Jim Cramer: Fed Minutes and Oil Hit the Market

Jim Cramer: Fed Minutes and Oil Hit the Market

Why you can't blame the president for Wednesday's weakness.

Jim Cramer: The Fundamentals on the Eve of Earnings Seem Pretty Darned Good

Jim Cramer: The Fundamentals on the Eve of Earnings Seem Pretty Darned Good

But If you want to know what I think could work the loudest here? How about Amazon?

Why Uber's Self-Driving Car Fatality Won't End Autonomous Driving

Why Uber's Self-Driving Car Fatality Won't End Autonomous Driving

The fatality that came at the hands of a self-driving Uber vehicle was tragic. But keep in mind, self-driving cars will be safer than human drivers in the not-too-distant future.

Bristol-Myers Squibb To Hold Investor Event To Discuss AACR Highlights

Bristol-Myers Squibb To Hold Investor Event To Discuss AACR Highlights

Bristol-Myers Squibb Company (NYSE: BMY) will hold an investor event on Monday, April 16, 2018 at 6:00 p.

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Bristol-Myers Squibb Company To Contact The Firm

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Bristol-Myers Squibb Company To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf...

Women's History Month: Nancy Lieberman -- Still Law Firm's Youngest Partner Ever

Women's History Month: Nancy Lieberman -- Still Law Firm's Youngest Partner Ever

For Women's History Month, Alpha Rising sat down with Nancy Lieberman, Of Counsel at Skadden, Arps. She was and still is the youngest person to ever make partner at her firm. She has worked on some of the biggest M&A deals in history -- and we should mention -- she's in a wheelchair and barely as use of her hands. Feel like a slacker yet? Good. Watch.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Bristol-Myers Squibb Company Of Class Action Lawsuit And Upcoming Deadline - BMY

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Bristol-Myers Squibb Company Of Class Action Lawsuit And Upcoming Deadline - BMY

Pomerantz LLP announces that a class action lawsuit has been filed against Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company") (NYSE:BMY) and certain of its officers.

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo Four-Week Dosing Schedule For Advanced Melanoma And Previously Treated Renal Cell Carcinoma

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo Four-Week Dosing Schedule For Advanced Melanoma And Previously Treated Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of an every four-week (Q4W) Opdivo...

Bristol-Myers Squibb Could Trade Sideways Till the Bull Returns

Bristol-Myers Squibb Could Trade Sideways Till the Bull Returns

Let's check out the charts and indicators for some guidance.

53 Value Stocks That the Federal Reserve May Make Unbeatable Buys

53 Value Stocks That the Federal Reserve May Make Unbeatable Buys

Value stocks haven't done well in the era of easy money, with cash piling into growth names. But, that could be about to change.

BMY LOSS NOTICE: Rosen Law Firm Reminds Bristol-Myers Squibb Company Investors Of Important April 10, 2018 Deadline In Class Action - BMY

BMY LOSS NOTICE: Rosen Law Firm Reminds Bristol-Myers Squibb Company Investors Of Important April 10, 2018 Deadline In Class Action - BMY

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Bristol-Myers Squibb Company (NYSE: BMY) from January 27, 2015 through October 9, 2016, inclusive (the "Class Period") of the...

Pfizer CEO Ian Read Gets 61% Raise to Keep Him From Considering Retirement

Pfizer CEO Ian Read Gets 61% Raise to Keep Him From Considering Retirement

Pfizer's CEO Ian Read could make almost $28 million in the next year to keep him from retiring. Strangely enough, he may earn it given the healthcare and political environment.

Research From Bristol-Myers Squibb's Innovative Oncology Development Program To Be Presented At AACR 2018 Demonstrates Commitment To Advancing Precision Medicine Research For Patients With Cancer

Research From Bristol-Myers Squibb's Innovative Oncology Development Program To Be Presented At AACR 2018 Demonstrates Commitment To Advancing Precision Medicine Research For Patients With Cancer

Bristol-Myers Squibb Company (NYSE:BMY) today announced the presentation of new data showcasing advances in the science of Immuno-Oncology at the American Association for Cancer Research (AACR) Annual Meeting in...

Bristol-Myers Squibb To Announce Results For First Quarter 2018 On April 26

Bristol-Myers Squibb To Announce Results For First Quarter 2018 On April 26

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2018 on Thursday, April 26, 2018.

The Klein Law Firm Reminds Investors Of A Class Action On Behalf Of Bristol-Myers Squibb Company Shareholders And A Lead Plaintiff Deadline Of April 10, 2018 (BMY)

The Klein Law Firm Reminds Investors Of A Class Action On Behalf Of Bristol-Myers Squibb Company Shareholders And A Lead Plaintiff Deadline Of April 10, 2018 (BMY)

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Bristol-Myers Squibb Company (NYSE:BMY) who purchased shares between January 27, 2015 and October 9, 2016.

The Klein Law Firm Reminds Investors Of A Class Action On Behalf Of Bristol-Myers Squibb Company Shareholders And A Lead Plaintiff Deadline Of April 10, 2018

The Klein Law Firm Reminds Investors Of A Class Action On Behalf Of Bristol-Myers Squibb Company Shareholders And A Lead Plaintiff Deadline Of April 10, 2018

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Bristol-Myers Squibb Company (NYSE: BMY) who purchased shares between January 27, 2015 and October 9, 2016.

Jim Cramer: Will the Techs Be Challenged, Too?

Jim Cramer: Will the Techs Be Challenged, Too?

The theft of intellectual property can be confronted by a Section 301 challenge directly from the trade representative.

TheStreet Quant Rating: C+ (Hold)